Precipio, Inc. presents findings on its BCR::ABL1 assay at ASH, showcasing improved performance and patient care impacts.
Quiver AI Summary
Precipio, Inc., a company specializing in cancer diagnostics, announced it will present findings from a joint study with Memorial Sloan Kettering at the ASH Meeting in Orlando on December 8, 2025. The study, which involved 895 patient samples, shows that Precipio's BCR::ABL1 assay outperforms two leading platforms while positively impacting patient care and enhancing laboratory workflows. The presentation will include a poster of the study abstract and a discussion of the results. Precipio aims to reduce cancer misdiagnoses through its innovative diagnostic products and services and actively communicates updates through its website and social media.
Potential Positives
- Precipio is showcasing significant findings from a joint study with Memorial Sloan Kettering, highlighting the superior performance of its BCR::ABL1 assay over two leading platforms.
- The study, involving 895 patient samples, demonstrates positive impacts on patient care and improvements in laboratory workflows, which could enhance the company's reputation in the diagnostics field.
- Presentation at the ASH Meeting provides Precipio with a platform to reach key stakeholders in the healthcare community, potentially leading to increased visibility and collaboration opportunities.
- Precipio's mission to address cancer misdiagnoses through innovative diagnostic technologies positions the company favorably in a critical area of healthcare, appealing to both investors and consumers focused on patient outcomes.
Potential Negatives
- The press release contains forward-looking statements, which may lead to uncertainty as they involve projections that could be affected by numerous risks and factors.
- There is a lack of specific details regarding the financial implications or commercial plans associated with the successful results of the BCR::ABL1 assay, which may lead to questions about future profitability.
- The emphasis on the company's mission to reduce misdiagnoses may imply previous challenges or shortcomings in the diagnostics industry that could negatively reflect on their credibility.
FAQ
What is the focus of Precipio, Inc.?
Precipio, Inc. focuses on developing innovative cancer diagnostics to address misdiagnosis and improve patient outcomes.
What key study will Precipio present at the ASH Meeting?
The study evaluates Precipio’s BCR::ABL1 assay and its performance through 895 patient samples in collaboration with Memorial Sloan Kettering.
When and where is the study presentation scheduled?
The presentation is scheduled for December 8th, from 6:00-8:00pm at the OCCC room in West Halls B3-B4 in Orlando, Florida.
How does Precipio improve laboratory workflows?
Precipio’s products enhance laboratory workflows by delivering higher accuracy and ultimately better patient outcomes, while reducing healthcare costs.
Where can I find more information about Precipio?
You can visit Precipio's website at https://www.precipiodx.com/ or follow them on social media platforms like LinkedIn and X.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PRPO Insider Trading Activity
$PRPO insiders have traded $PRPO stock on the open market 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $PRPO stock by insiders over the last 6 months:
- KATHLEEN LAPORTE sold 6,152 shares for an estimated $123,409
- AHMED ZAKI SABET (Chief Operating Officer) has made 2 purchases buying 56 shares for an estimated $992 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PRPO Revenue
$PRPO had revenues of $6.8M in Q3 2025. This is an increase of 29.91% from the same period in the prior year.
You can track PRPO financials on Quiver Quantitative's PRPO stock page.
$PRPO Hedge Fund Activity
We have seen 9 institutional investors add shares of $PRPO stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AMH EQUITY LTD added 103,210 shares (+370.1%) to their portfolio in Q3 2025, for an estimated $1,836,105
- TOPLINE CAPITAL MANAGEMENT, LLC added 65,096 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,158,057
- EVERNEST FINANCIAL ADVISORS, LLC added 21,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $373,590
- RENAISSANCE TECHNOLOGIES LLC added 13,100 shares (+inf%) to their portfolio in Q3 2025, for an estimated $233,049
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 10,797 shares (+inf%) to their portfolio in Q3 2025, for an estimated $192,078
- DRW SECURITIES, LLC added 10,572 shares (+inf%) to their portfolio in Q3 2025, for an estimated $188,075
- VANGUARD GROUP INC added 2,542 shares (+14.4%) to their portfolio in Q3 2025, for an estimated $45,222
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEW HAVEN, Conn., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) will be presenting at ASH the findings of a joint study conducted with scientific collaborators from Memorial Sloan Kettering in New York, evaluating Precipio’s BCR::ABL1 assay.
The data from a comprehensive study includes 895 patient samples and demonstrates superior performance of the assay, while showing concordance with two other leading platforms. The study shows clear, positive impacts on patient care alongside substantial improvements in laboratory workflows.
Poster presentation of the study abstract, and results discussion are scheduled for Monday December 8 th from 6:00-8:00pm at the OCCC room in West Halls B3-B4 at the ASH Meeting in Orlando, Florida.
About Precipio
Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis.
Availability of Other Information About Precipio
For more information, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) ( @PrecipioDx ) and LinkedIn (Precipio) and on Facebook . Investors and others should note that we communicate with our investors and the public using our company website ( https://www.precipiodx.com ), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, adjusted EBITDA, plans, objectives, expectations, growth or profitability and our potential to reach financial independence are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
